Arcutis Biotherapeutics Inc’s recent filing unveils that its Officer Watanabe Todd Franklin acquired Company’s shares for reported $26282.0 on Mar 24 ’25. In the deal valued at $17.52 per share,1,500 shares were bought.
Then, Watanabe Todd Franklin sold 1,200 shares, generating $21,137 in total proceeds. Upon selling the shares at $17.61, the insider now owns 928,914 shares.
Before that, Watanabe Todd Franklin bought 1,200 shares. Arcutis Biotherapeutics Inc shares valued at $21,137 were divested by the Officer at a price of $17.61 per share.
H.C. Wainwright initiated its Arcutis Biotherapeutics Inc [ARQT] rating to a Buy in a research note published on December 30, 2024; the price target was $19. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. Mizuho also remained covering ARQT and has increased its forecast on January 03, 2024 with a “Buy” recommendation from previously “Neutral” rating. Mizuho revised its rating on October 26, 2023. It rated ARQT as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ARQT
On Monday, Arcutis Biotherapeutics Inc [NASDAQ:ARQT] saw its stock jump 1.65% to $17.29. Over the last five days, the stock has gained 5.30%. Arcutis Biotherapeutics Inc shares have risen nearly 24.12% since the year began. Nevertheless, the stocks have risen 60.09% over the past one year. While a 52-week high of $17.70 was reached on 03/17/25, a 52-week low of $6.99 was recorded on 02/11/25. SMA at 50 days reached $13.79, while 200 days put it at $11.20.
Levels Of Support And Resistance For ARQT Stock
The 24-hour chart illustrates a support level at 16.92, which if violated will result in even more drops to 16.55. On the upside, there is a resistance level at 17.65. A further resistance level may holdings at 18.01. The Relative Strength Index (RSI) on the 14-day chart is 67.14, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.42, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 9.32%. Stochastics %K at 86.99% indicates the stock is a selling.
How much short interest is there in Arcutis Biotherapeutics Inc?
A steep rise in short interest was recorded in Arcutis Biotherapeutics Inc stocks on 2025-02-28, growing by 0.85 million shares to a total of 19.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 18.91 million shares. There was a rise of 4.31%, which implies that there is a positive sentiment for the stock.
